Sex-differential effects of olanzapine vs. aripiprazole on glucose and lipid metabolism in first-episode schizophrenia

Objective: To compare sex difference in metabolic effect of olanzapine versus aripiprazole on schizophrenia. Methods: A twelve-week prospective open-label cohort study to compare four subgroups according to first-episode schizophrenia patients' type of drug usage and sex: female aripiprazole (n...

Full description

Saved in:
Bibliographic Details
Published in:Revista de psiquiatria clínica 2019-03, Vol.46 (2), p.33-39
Main Authors: Zhou, Xue-Mei, Hu, Mao-Rong, Gong, Mei-Yu, Zou, Xue-Liang, Yu, ZHi-Min
Format: Article
Language:eng ; por
Subjects:
Analysis
Antipsychotic agents
Aripiprazole
Body mass index
Cholesterol
Criminal investigation
Email
Fasting
Glucose
Glucose metabolism
Health
Low density lipoproteins
Medical research
MEDICINE, GENERAL & INTERNAL
Mental health
Mental health services
Olanzapine
Physiological aspects
Psychiatrists
PSYCHIATRY
Schizophrenia
Sex differences (Psychology)
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To compare sex difference in metabolic effect of olanzapine versus aripiprazole on schizophrenia. Methods: A twelve-week prospective open-label cohort study to compare four subgroups according to first-episode schizophrenia patients' type of drug usage and sex: female aripiprazole (n = 11), male aripiprazole (n = 11), female olanzapine (n = 10), and male olanzapine (n = 11) for body mass index, fasting serum triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and fasting glucose. Results: Aripiprazole may be associated with weight gain in female patients with low-baseline weight. Aripiprazole may have an adverse effect of weight and favorable effects of circulating glucose and lipid on female over male schizophrenia patients. The aripiprazole-induced changes in glucose and lipid may be independent of body fat storage, especially for female schizophrenia patients. Olanzapine may have adverse effects of weight, glucose and lipid profiles on female over male schizophrenic patients. Discussion: Our findings fill the gap in knowledge and provide a sex-specific guidance to psychiatrist better tailoring treatment to individual sex-differential characteristics and a key clue to understand the sex-differential mechanism of antipsychotics-induced metabolic dysfunction. ZHou XM et al. / Arch Clin Psychiatry. 2019;46(2):33-9 Keywords: Schizophrenia, sex difference, glucose and lipid, olanzapine, aripiprazole.
ISSN:0101-6083
1806-938X
1806-938X
DOI:10.1590/0101-60830000000189